Table 2 Summary of treatments received, per disease category, as defined in table 3.

Type of treatment	RCD I n = 43 (%)	RCD II n = 50 (%)	Secondary EATL n = 26 (%)	De novo EATL n = 13 (%)	Treatment protocol
Prednisone/topical steroids only	31 (72)	16 (32)	0	0	Prednisone 40 mg/day for 6 weeks, tapered to 10 mg/day over 6 weeks and, if possible, tapered to 2.5–0 mg daily after 3 months, depending on response
Prednisone + azathioprine8	12 (28)	34 (68)*	0	0	Prednisone (as above) + Azathioprine 2 mg/kg/day for ⩾52 weeks
Prednisone + azathioprine followed by 2‐CDA17	0	23 (46)	0	0	Prednisone + Azathioprine as above. 2‐CDA (0.1 mg/kg/day) intravenously for 5 days, in 1–3 courses every 6 months depending on response
CHOP	0	0	16 (61.5)	7 (53)	Standard CHOP 6–8 cycles
ASCT20,27	0	6 (12)	1	3 (30)	Pretreatment with 1–3 courses of 2‐CDA, leucopheresis, preconditioning (Melphalan+Fludarabine) + ASCT
Partial small‐intestine resection	0	9 (18)	6 (23)*	8 (61.5)*	–

2‐CDA, cadribine; ASCT, autologous stem‐cell transplantation; CHOP, cyclophosphamide, doxorubicine, vincristine and prednisone; EATL, enteropathy‐associated T‐cell lymphoma; RCD, refractory coeliac disease.

All RCD I, RCD II and secondary EATL patients have followed a gluten‐free diet.*p = 0.025.